Examkin

Soru

Zorluk: KolayMonitoring and Treatment Evaluation

A 2424-year-old man with type 11 diabetes mellitus is admitted to the intensive care unit for diabetic ketoacidosis. He is initially managed with vigorous intravenous normal saline resuscitation and a continuous regular insulin infusion. Arrange the following sequential steps regarding the monitoring of his condition and the subsequent adjustment of his therapeutic regimen in the correct chronological order, from first to last.

  1. 1Assess point-of-care blood glucose hourly and calculate the serum anion gap every 22 to 44 hours.
  2. 2Add 5%5\% dextrose to the intravenous maintenance fluids once the blood glucose concentration falls below 200 mg/dL200\text{ mg/dL}.
  3. 3Administer a dose of subcutaneous basal insulin when the anion gap normalizes and the patient is able to tolerate oral intake.
  4. 4Discontinue the continuous intravenous insulin infusion 11 to 22 hours after the subcutaneous insulin dose is given.

Cevap

The correct sequence is: monitor glucose and the anion gap first, add dextrose to intravenous fluids when glucose falls below 200 mg/dL200\text{ mg/dL}, administer subcutaneous insulin once the anion gap closes, and finally discontinue the intravenous insulin infusion 11 to 22 hours later.
The management of diabetic ketoacidosis requires sequential monitoring and careful therapeutic adjustments. First, rigorous tracking of glucose and the anion gap establishes the patient's baseline trajectory. Second, because blood glucose normalizes more rapidly than ketones clear, dextrose must be added to the intravenous fluids so that the insulin drip can safely continue to halt ketogenesis without causing hypoglycemia. Third, once ketoacidosis is fully resolved (indicated by a closed anion gap) and the patient can tolerate an oral diet, a subcutaneous basal insulin dose is administered. Finally, the continuous intravenous insulin must be maintained for an additional 11 to 22 hours after the subcutaneous injection to prevent a critical gap in insulin coverage, which would otherwise trigger rebound ketoacidosis.

Adım Adım Çözüm

1
Establish the baseline monitoring frequency for metabolic parameters.
Blood glucose is tracked hourly and the basic metabolic panel is checked every 22 to 44 hours.
This intensive monitoring safely tracks the resolution of ketoacidosis and detects early signs of iatrogenic hypoglycemia or electrolyte shifts.
2
Adjust the composition of the intravenous fluids based on glucose trends.
Intravenous dextrose is added to the fluid regimen when the blood glucose reaches 200 mg/dL200\text{ mg/dL}.
The regular insulin infusion must be maintained to clear serum ketones even after glucose levels normalize; dextrose prevents the patient from becoming severely hypoglycemic.
3
Initiate subcutaneous maintenance therapy based on metabolic resolution.
Subcutaneous basal insulin is administered once the anion gap closes (leq12 mEq/L\\leq 12\text{ mEq/L}) and the patient can eat.
Resolution of the elevated anion gap indicates that the underlying state of ketogenesis has been corrected.
4
Safely stop the continuous intravenous therapy.
The intravenous insulin pump is turned off 11 to 22 hours after the subcutaneous injection.
This overlap period ensures continuous systemic insulin coverage while the subcutaneous depot is absorbed into the bloodstream.

Anahtar Kavram

Monitoring and stepwise transition of therapy in diabetic ketoacidosis
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru